0000899243-20-026210.txt : 20200923 0000899243-20-026210.hdr.sgml : 20200923 20200923213537 ACCESSION NUMBER: 0000899243-20-026210 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200921 FILED AS OF DATE: 20200923 DATE AS OF CHANGE: 20200923 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ENRIGHT PATRICK G CENTRAL INDEX KEY: 0001253886 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37519 FILM NUMBER: 201193406 MAIL ADDRESS: STREET 1: CO LONGITUDE CAPITAL PARTNERS LLC STREET 2: 800 EL CAMINO REAL, SUITE 220 CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc. CENTRAL INDEX KEY: 0001631650 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452748244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 BUSINESS PHONE: (650) 614-5220 MAIL ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 FORMER COMPANY: FORMER CONFORMED NAME: Allergen Research Corp DATE OF NAME CHANGE: 20150123 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-09-21 0 0001631650 Aimmune Therapeutics, Inc. AIMT 0001253886 ENRIGHT PATRICK G C/O LONGITUDE CAPITAL PARTNERS II, LLC 2740 SAND HILL ROAD, SECOND FLOOR MENLO PARK CA 94025 1 0 0 0 Common Stock, $0.0001 par value 2020-09-21 4 J 0 6113134 0.00 D 0 I By: LVP2 Common Stock, $0.0001 par value 2020-09-21 4 J 0 91697 0.00 A 91697 I By: LCP2 Common Stock, $0.0001 par value 78401 D Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners II, L.P. ("LVP2") to its general and limited partners. Reflects shares that were held by LVP2. Longitude Capital Partners II, LLC ("LCP2") is the general partner of LVP2 and may be deemed to share voting and investment power over the shares of the Issuer held by LVP2. The Reporting Person is a managing member of LCP2 and in his capacity as such may be deemed to share voting and investment power over the shares held by LVP2. Each of LCP2 and the Reporting Person disclaim beneficial ownership over these securities and this report shall not be deemed an admission that either of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Represents a change in the form of ownership of LCP2 by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by LVP2. Reflects shares held by LCP2. The Reporting Person is a managing member of LCP2 and in his capacity as such may be deemed to share voting and investment power over the shares held by LCP2. The Reporting Person disclaims beneficial ownership over these securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. /s/ Patrick G. Enright 2020-09-23